Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 17/20 | 0.66 |
| ▸ | AURKA | O14965 | 15/20 | 0.66 |
| ▸ | GSK3B | P49841 | 8/20 | 0.66 |
| ▸ | SRC | P12931 | 7/20 | 0.66 |
| ▸ | AURKC | Q9UQB9 | 3/20 | 0.66 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18154710 | 0.87 | AURKB (0.66) | AURKBAURKAGSK3BSRCAURKC | |
| SCHEMBL18154673 | 0.85 | AURKB (0.63) | AURKBAURKAGSK3BSRCAURKC | |
| SCHEMBL19990669 | 0.84 | AURKB (0.62) | AURKBAURKAGSK3BSRCAURKC | |
| SCHEMBL18154755 | 0.84 | PLK4 (0.73) | AURKBAURKAGSK3BSRCAURKC | |
| SCHEMBL18154838 | 0.84 | AURKB (0.62) | AURKBAURKAGSK3BSRCAURKC | |
| SCHEMBL18154812 | 0.84 | PLK4 (0.72) | AURKBAURKAGSK3BSRCAURKC | |
| SCHEMBL19990501 | 0.84 | PLK4 (0.72) | AURKBAURKAGSK3BSRCAURKC | |
| SCHEMBL19990895 | 0.83 | PLK4 (0.83) | AURKBAURKAGSK3BSRCAURKC | |
| SCHEMBL18154766 | 0.83 | PLK4 (0.71) | AURKBAURKAGSK3BSRCAURKC | |
| SCHEMBL19990444 | 0.83 | AURKB (0.58) | AURKBAURKAGSK3BSRCAURKC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752612-B2 | PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2020-08-25 | — | — | US | disclosed |
| US-20180086739-A1 | PLK4 INHIBITORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2018-03-29 | — | — | US | disclosed |
| WO-2016166604-A1 | PLK4 INHIBITORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086739-A1 | PLK4 INHIBITORS | PLK4, PLK2, PLK3 | AURKB 23/4885AURKA 32/4885GSK3B 73/4885 |
| US-10752612-B2 | PLK4 inhibitors | PLK4, PLK2, PLK3 | AURKB 23/4885AURKA 32/4885GSK3B 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.